免疫检查点抑制剂联合化疗的模式探讨
本文综述了免疫检查点抑制剂联合标准化疗在多种实体瘤中的临床试验证据,包括非小细胞肺癌、小细胞肺癌、尿路上皮癌、头颈癌、胃癌、食管癌及三阴性乳腺癌和胰腺癌。文章探讨了协同作用的潜在机制,并指出化疗方案尚未针对联合治疗优化,新辅助和辅助方案是优化方向。
要点
- PD-1/PD-L1抑制剂联合标准化疗已在多种实体瘤的III期试验中获证据支持。
- 协同机制包括免疫原性细胞死亡、抗血管生成、髓系抑制细胞清除及淋巴细胞减少。
- 化疗方案未针对联合治疗优化,可能导致部分临床试验失败。
核心结论
- PD-1/PD-L1阻断免疫治疗联合标准化疗已在多种恶性肿瘤的III期临床试验中获得证据支持。
研究设计与样本
- 本文为综述,聚焦免疫检查点抑制剂联合化疗的临床试验证据、协同机制及方案优化机会。
主要发现
- 已在非小细胞肺癌、小细胞肺癌、尿路上皮癌、头颈癌、胃癌和食管癌中报告成功。
- 在三阴性乳腺癌和胰腺恶性肿瘤中已获得有前景的结果。
- 协同机制包括免疫原性肿瘤细胞死亡、抗血管生成、选择性清除髓系免疫抑制细胞及淋巴细胞减少。
临床怎么用
- 可考虑在新辅助和辅助方案中应用化学免疫治疗以最大化疗效。
- 需注意化疗方案尚未针对联合治疗优化,应关注方案选择对疗效的影响。
局限性
- 化疗方案未针对化学免疫联合治疗优化,可能解释部分近期临床试验的失望结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical trials. Success has been reported in non-small and small cell lung carcinomas and urothelial, head and neck, gastric, and esophageal cancers, and promising results are already available in triple-negative breast and pancreatic malignancies. The potential mechanisms of synergy include immunogenic tumor cell death, antiangiogenesis, selective depletion of myeloid immunosuppressive cells, and lymphopenia, which reduces regulatory T cells and makes room for proliferation of effector T cells. However, chemotherapy regimens have not been optimized for such combinations, perhaps explaining some recent clinical trial disappointments. Approaches to make the most of chemoimmunotherapy include neoadjuvant and adjuvant schemes.Significance: Immunotherapy of cancer based on PD-1/PD-L1 blockade has prompted a revolution in cancer clinical management. Evidence in phase III clinical trials already supports combinations of immunotherapy with standard-of-care chemotherapy for a number of malignant diseases. This review focuses on such evidence and provides an overview of the potential synergistic mechanisms of action and the opportunities to optimize chemoimmunotherapy regimens.
引用
- Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, et al. Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021. PMID: 33712487. doi:10.1158/2159-8290.CD-20-1312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。